Try a new search

Format these results:

Searched for:

in-biosketch:true

person:segevd01

Total Results:

1178


Immunogenicity after heterologous third dose COVID-19 vaccination in a heart transplant recipient [Letter]

Mehta, Sapna A; Reyentovich, Alex; Montgomery, Robert A; Segev, Dorry L; Gebel, Howard M; Bray, Robert A; Samanovic, Marie I; Cornelius, Amber R; Mulligan, Mark J; Herati, Ramin S
PMID: 35107835
ISSN: 1399-0012
CID: 5153612

Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19

Alejo, Jennifer L; Mitchell, Jonathan; Chang, Amy; Chiang, Teresa P Y; Massie, Allan B; Segev, Dorry L; Makary, Martin A
PMID: 35113143
ISSN: 1538-3598
CID: 5151912

Don't Stop Thinking About Tomorrow: Ascertainment Bias in Pre-post Design Transplant Registry Studies [Editorial]

Motter, Jennifer D; Segev, Dorry L; Massie, Allan B
PMID: 35112490
ISSN: 1600-6143
CID: 5151902

Transplant centers that assess frailty as part of clinical practice have better outcomes

Chen, Xiaomeng; Liu, Yi; Thompson, Valerie; Chu, Nadia M; King, Elizabeth A; Walston, Jeremy D; Kobashigawa, Jon A; Dadhania, Darshana M; Segev, Dorry L; McAdams-DeMarco, Mara A
BACKGROUND:Frailty predicts adverse post-kidney transplant (KT) outcomes, yet the impact of frailty assessment on center-level outcomes remains unclear. We sought to test whether transplant centers assessing frailty as part of clinical practice have better pre- and post-KT outcomes in all adult patients (≥18 years) and older patients (≥65 years). METHODS:In a survey of US transplant centers (11/2017-4/2018), 132 (response rate = 65.3%) centers reported their frailty assessment practices (frequency and specific tool) at KT evaluation and admission. Assessment frequency was categorized as never, sometime, and always; type of assessment tool was categorized as none, validated (for post-KT risk prediction), and any other tool. Center characteristics and clinical outcomes for adult patients during 2017-2019 were gleaned from the transplant national registry (Scientific Registry of Transplant Recipients). Poisson regression was used to estimate incidence rate ratios (IRRs) of waitlist outcomes (waitlist mortality, transplantation) in candidates and IRRs of post-KT outcomes (all-cause mortality, death-censored graft loss) in recipients by frailty assessment frequency. We also estimated IRRs of waitlist outcomes by type of assessment tool at evaluation. All models were adjusted for case mix and center characteristics. RESULTS:Assessing frailty at evaluation was associated with lower waitlist mortality rate (always IRR = 0.91,95%CI:0.84-0.99; sometimes = 0.89,95%CI:0.83-0.96) and KT rate (always = 0.94,95%CI:0.91-0.97; sometimes = 0.88,95%CI:0.85-0.90); the associations with waitlist mortality rate (always = 0.86,95%CI:0.74-0.99; sometimes = 0.83,95%CI:0.73-0.94) and KT rate (always = 0.82,95%CI:0.77-0.88; sometimes = 0.92,95%CI:0.87-0.98) were stronger in older patients. Furthermore, using validated (IRR = 0.90,95%CI:0.88-0.92) or any other tool (IRR = 0.90,95%CI:0.87-0.93) at evaluation was associated lower KT rate, while only using a validated tool was associated with lower waitlist mortality rate (IRR = 0.89,95%CI:0.83-0.96), especially in older patients (IRR = 0.82,95%CI:0.72-0.93). At admission for KT, always assessing frailty was associated with a lower graft loss rate (IRR = 0.71,95%CI:0.54-0.92) but not with mortality (IRR = 0.93,95%CI:0.76-1.13). CONCLUSIONS:Assessing frailty at evaluation is associated with lower KT rate, while only using a validated frailty assessment tool is associated with better survival, particularly in older candidates. Centers always assessing frailty at admission are likely to have better graft survival rates. Transplant centers may utilize validated frailty assessment tools to secure KT access for appropriate candidates and to better allocate health care resources for patients identified as frail, particularly for older patients.
PMID: 35086480
ISSN: 1471-2318
CID: 5150292

Long-term Frailty Trajectories After Kidney Transplantation [Meeting Abstract]

Ruck, Jessica; Chu, Nadia; Chen, Xiaomeng; Bandeen-Roche, Karen; Norman, Silas; Segev, Dorry; McAdams-DeMarco, Mara
ISI:000739470700169
ISSN: 1600-6135
CID: 5133682

Y A Machine Learning Model for Predicting Antibody Response to a 2-Dose SARS-CoV-2 mRNA Vaccine Series in Transplant Recipients [Meeting Abstract]

Alejo, Jennifer; Mitchell, Jonathan; Chiang, Teresa; Abedon, Aura; Werbel, William; Avery, Robin; Tobian, Aaron; Massie, Allan; Garonzik-Wang, Jacqueline; Segev, Dorry; Bae, Sunjae
ISI:000739470700024
ISSN: 1600-6135
CID: 5133542

Increased Logistical Complexity In Circle-Based Organ Allocation [Meeting Abstract]

Wood, Nicholas; VanDerwerken, Douglas; Segev, Dorry; Gentry, Sommer
ISI:000739470700198
ISSN: 1600-6135
CID: 5133692

Opportunities for Improved Efficiency in Kidney Distribution: A Comparison of Center-Specified UNet Donor Criteria to Actual Kidney Acceptance Practices [Meeting Abstract]

Zeiser, Laura; Gentry, Sommer; Segev, Dorry; Massie, Allan
ISI:000739470700207
ISSN: 1600-6135
CID: 5133702

Antibody Response to a Third dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: mRNA and Viral Vector Boosters [Meeting Abstract]

Alejo, Jennifer; Bae, Sunjae; Mitchell, Jonathan; Chiang, Teresa; Boyarsky, Brian; Abedon, Aura; Chang, Amy; Avery, Robin; Tobian, Aaron; Massie, Allan; Levan, Macey; Warren, Daniel; Garonzik-Wang, Jacqueline; Segev, Dorry; Werbel, William
ISI:000739470700006
ISSN: 1600-6135
CID: 5133492

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Frey, Sarah; Chiang, Teresa Po-Yu; Connolly, Caoilfhionn M; Teles, Mayan; Alejo, Jennifer L; Boyarsky, Brian J; Christopher-Stine, Lisa; Werbel, William A; Massie, Allan B; Segev, Dorry L; Paik, Julie J
PMCID:8765758
PMID: 35072108
ISSN: 2665-9913
CID: 5127932